Today, only 12% of investigational drugs win marketing approval in the United States.
The pressure is on to deliver new products faster and more efficiently, and this herculean task doesn't come without difficulties.
Some challenges include (but are certainly not limited to):
Download this whitepaper and discover additional challenges as well as aspects to consider when developing a supply plan, the influence of early decisions and impact on outcome as a trial progresses, and how decisions can put patients and the trial at risk.
​​